257 results about "Xanthine oxidase" patented technology

(Aza)indolizine derivatives represented by Formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, salts thereof or the like. In Formula (I), 0 to 2 of X¹, X², X³ and X⁴ are a nitrogen atom and the others are CR¹; one of T¹ and T² represents cyano and the other represents a group represented by Formula (A), with the proviso that when T¹ is cyano, at least one of X¹ to X⁴ is a nitrogen atom; R¹ independently represents a hydrogen atom, a halogen atom, a hydroxy group, C_1-6 alkyl, C_1-6 alkoxy or the like; ring U represents a benzene ring or the like; m represents integral number from 0 to 2; R² independently represents a fluorine atom, a hydroxy group or the like.

The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I):

wherein Y¹ represents N or C(R⁴); Y² represents N or C(R⁵); R⁴ and R⁵ independently represent an alkyl group, a hydrogen atom etc.; one of R¹ and R² represents an optionally substituted aryl group, an alkoxy group or an optionally substituted heterocyclic group; the other of R¹ and R² represents a haloalkyl group, a cyano group, a halogen atom etc.; and R³ represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.

The invention relates to an extraction method for a Synsepalum dulcificum Denill tree branch and leaf extract. The extraction method comprises the following steps of: crushing Synsepalum dulcificum Denill tree branches and leaves to obtain an extracted raw material; adding ethanol water; performing reflux extraction for 2-5 hours; filtering; performing reduced pressure distillation on supernate; performing freeze drying to obtain branch and leaf crude extract dry powder; dissolving the branch and leaf crude extract dry powder in water; performing macroporous resin treatment; then, eluting by using the ethanol water to obtain drips; and respectively performing vacuum concentration and the freeze drying to obtain a refined branch and leaf extract. The total phenol content of the obtained extract is 66.5 percent, and the total phenol content of a branch extract is 84.1 percent. The diphenylpicrylphenylhydrazine (DPPH) scavenging activity of the extract is 7.9 and 7.8 times of that of glutathione, and the oxygen radical absorbing capacity of the extract is 7.0 and 6.2 times of that of the glutathione. The extract is good in inhibitory activity on xanthine oxidase and can be used for preparing antioxidants, gout suppressants and health-care products.

The invention relates to use of vegetable extract in inhibiting xanthine oxidase (XO) and application in preparing food for preventing and treating hyperuricemia or gout. The vegetable extract is prepared by the following steps: a methanol extraction process: removing impurities from fresh vegetable, and removing moisture in an electrothermal blowing drying box at 40 DEG C; crushing the vegetableinto powder by a crusher; weighing a certain amount of dry vegetable into a conical flask, and extracting by methanol ultrasonic wave twice for 45 minutes in each extraction; filtering to remove the filter residue; recycling the solvent from the filtrate by a rotary evaporator, and drying the remainder in an electrothermal vacuum drying box to obtain extractum; and applying the vegetable methanolextract to an in vitro XO inhibition test so as to screen out the vegetable crude extract with the effect on inhibiting the XO. The invention provides an reference on diet for preventing and treatinggout or hyperuricemia.

The present invention discloses a method for the preparation of a protein peptide, peptide powder prepared thereby, and use of the peptide powder in hypouricemic food products or health care products. The peptide powder is capable of inhibiting the activity of xanthine oxidase and effectively reducing uric acid. The method in an example of the present invention comprises: mincing the tuna, heating with steam or water to obtain a pretreated tuna, enzymolysing the pretreated tuna, deactivating the enzyme, centrifuging, removing impurities to obtain a supernatant, concentrating, and drying to obtain the peptide powder of interest.

The invention provides an Arthrobacter and an application of the Arthrobacter for generating xanthine oxidase and a preparation method thereof. The Arthrobacter XL2006 derives from nature and the16S rRNA sequence of the Arthrobacter XL2006 is shown in a sequence table SEQ ID NO.1. The Arthrobacter XL2006 is applied to producing, extracting and purifying the xanthine oxidase and preparing a diagnostic kit. The Arthrobacter XL2006 is characterized by the production of the xanthine oxidase and can adopt hypoxanthine or xanthine as a unique source of carbon and nitrogen and a unique energy source. The fermentation and the production of the xanthine oxidase are characterized by simple nutritional requirements, easy culture and short fermentation time; the produced xanthine oxidase has quite high activity, and strains provided by the invention are utilized to ferment and extract the xanthine oxidase and the prepared diagnostic kit can be applied to clinically testing the levels of hypoxanthine and xanthine in blood serum of patients.

The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal plasma uric acid level and the like. The present invention relates to fused heterocyclic derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of plasma uric acid level, prodrugs thereof, salts thereof or the like. In the formula (I), T represents trifluoromethyl, nitro or cyano; ring Q represents heteroaryl; X¹ and X² independently represent CH or N; ring U represents aryl or heteroaryl; m represents integral number from 0 to 2; n represents integral number from 0 to 3; R¹ represents a hydroxy group, amino or C_1-6 alkyl; R² represents C_1-6 alkyl, C_1-6 alkoxy C_1-6 alkyl or the like.

The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH₂, halogen, nitro, alkyl, alkoxy and the like; X¹, X² and X³ independently represent CR² or N; R¹ and R² independently represent halogen, cyano, haloalkyl, A-D-E-G, —N(-D-E-G)₂ and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO₂ and the like.

The invention relates to a 2-(3-cyano-4-alkoxy) phenyl-4-substituted thiazole-5-formic acid compound which has xanthine oxidase inhibitory activity and is shown in a general formula I, a composition and preparation methods thereof. The invention also relates to applications of the compound and the composition thereof to preparation of medicaments for treating and/or preventing hyperuricemia and gout diseases. In the formula I, R2 is substituted or unsubstituted phenyl or a substituted or unsubstituted heteroaromatic radical, R1 is a substitutive aliphatic group of a straight chain or a branched chain, substituted or unsubstituted alicyclic hydrocarbonyl or substituted or unsubstituted aryl alkyl and A is an oxygen atom, a sulfur atom or a nitrogen atom.

The present invention relates to the technical field of medicine, specifically to an application of salvianolic acid C in preparation of drugs for prevention and treatment of hyperuricemia. The results of the pharmacological test show that: the salvianolic acid C can be adopted as a xanthine oxidase (XO) inhibitor to prevent and treat hyperuricemia and complications of the hyperuricemia, wherein the complications caused by the hyperuricemia comprise: gout, gouty arthritis, gouty nephropathy, lithangiuria, cardiovascular diseases and other diseases.

The present invention relates to a composition for inhibiting xanthine oxidase comprising an effective amount of the extracts from Acacia spp.

The invention particularly relates to a xanthine oxidase inhibitory peptide. The amino acid sequence of the xanthine oxidase inhibitory peptide is Glu-Glu-Ala-Lys (EEAK). The IC50 value of the tetrapeptide EEAK on xanthine oxidase inhibitory activity is 173.00+/-0.06 [mu]M, the tetrapeptide EEAK has a continuous and stable inhibitory effect on xanthine oxidase, and the tetrapeptide EEAK has the outstanding advantages of safety, no toxic or side effect, easiness in absorption, industrialization and the like. The active tetrapeptide EEAK or the derivative thereof can be used for preparing gout treatment/prevention medicines or used as a functional food additive for long-term treatment and health care of gout patients, and has a wide application prospect and very important significance.

The invention discloses application of high mangiferin and aglycon thereof in preparation of a medicament for preventing and treating hyperuricemia and in particular relates to application of high mangiferin and aglycon thereof in preparation of a medicament for preventing and treating hyperuricemia as well as gout and lithangiuria brought by the hyperuricemia, and a medicine application way. The high mangiferin and aglycon thereof provided by the invention can be used for obviously reducing the concentration of serum uric acid in an animal for experiment and have the serum uric acid inhibition effect similar to that of a xanthine oxidase inhibition medicament allopurinol; and simultaneously, the high mangiferin and aglycon thereof provided by the invention can be used for obviously improving the concentration of uric acid in urine and have the uric acid excretion promoting function similar to that of a uric acid excretion promoting medicament probenecid. The high mangiferin and aglycon thereof provided by the invention are efficient, low in toxicity and high in safety, thus the high mangiferin and aglycon thereof are wide in application prospect.

The invention belongs to the technical field of a biosensor, and discloses an enzyme biosensor for detecting inosine monophosphate(IMP) and a preparation method and an application thereof. The lineardetection range of the enzyme biosensor is 0.313-210 microgram/L, and the detection limit is 0.238 microgram/L. The enzyme biosensor is formed by a reference electrode, a counter electrode and a modified electrode obtained by curing an IMP-sensitive substance recognition film on the surface of a working electrode. The substance recognition film is formed by a composite solution a, a double-enzymecomposite solution b formed by a 5'-nucleotidase solution and an xanthine oxidase solution by the volume ratio 1: 1, and a bovine serum albumin solution by the volume ratio of 1: 1: 1, wherein the composite solution a is composed of a MXene-Ti3C2Tx solution (T is selected from OH, O or F), a chitosan solution, a chloroauric acid solution and a chloroplatinic acid solution by the volume ratio of 12:1.2:1:1. The enzyme biosensor is simple, fast and accurate and high in sensitivity, and can be used for quantitative detection of inosine monophosphate(IMP) in food.

The invention belongs to the technical field of drug synthesis, and particularly relates to pentacetylgardenoside cyclohexanamide capable of reducing uric acid activity and a preparation method and application of the pentacetylgardenoside cyclohexanamide. The molecular structure formula of a compound is as follows (please see the specification of the formula). According to the pentacetylgardenoside cyclohexanamide, structural modification is conducted on gardenoside to improve the biological activity of the gardenoside, the functions of reducing the uric acid and protecting kidney areachieved,through an amide bond, acompound molecule can make the compound to effectively occupy thenarrow hydrophobic cavity of xanthine oxidase, meanwhile the compound further extends in the cavity, and formsMo-O-X coordination with an Mo ion, thus the inhibition activity of xanthine oxidase is enhanced, and the potential for drug formation is achieved. According to the pentacetylgardenoside cyclohexanamide with the functions of reducing the uric acid and protecting the kidney, the synthetic method is easy, the cost of the raw materials is low, and the structure is novel.

The invention relates to the technical field of medicines, in particular to application of polygonum capitatum in regulation of uric acid. Through research, it discovers that the polygonum capitatum can reduce uric acid content in serum of individuals with hyperuricemia by inhibiting the activity of xanthine oxidase in the liver, and can be well applied to regulating uric acid, treating diseases related to hyperuricemia or preparing drugs for treating, preventing, reducing and/or relieving diseases related to hyperuricemia. The polygonum capitatum has effects of resisting hyperuricemia and gout, and a brand-new, safe and effective natural drug for treating the hyperuricemia and the gout is provided.

Provided is a triarylcarboxylic acid derivative, or an isomer, a prodrug, a hydrate, a solvate, a polymorph, or a pharmaceutically acceptable salt thereof, represented by the following general formula (I):

wherein A is an optionally substituted aryl or heteroaryl, and B is an optionally substituted monocyclic heteroaryl; and a pharmaceutical composition comprising the same and a pharmaceutically acceptable carrier. The triarylcarboxylic acid derivative (I) exhibits potent xanthine oxidase inhibiting action and is therefore useful as a therapeutic agent for preventing or treating hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy and diabetic retinopathy.

The invention discloses a deuterium-substituted 2-phenylthiazole compound and a pharmaceutical composition thereof, and specifically relates to a deuterium-substituted 2-phenylthiazole compound with a general formula represented by formula (I), and a pharmaceutically acceptable salt thereof. At least one of R<3>, R<4>, and R<5> are used for representing deuterium or a substituent group containing deuterium. The deuterium-substituted 2-phenylthiazole compound is capable of inhibiting activity of xanthine oxidase. The deuterium-substituted 2-phenylthiazole compound or the pharmaceutically acceptable salt of the deuterium-substituted 2-phenylthiazole compound can be used for preparation of medicines used for preventing or treating hyperuricemia, gout, diabetic nephropathy, inflammatory diseases, and nervous system diseases.

The invention relates to a galloyl-glucoside derivative, application of a pharmaceutically acceptable salt of the galloyl-glucoside derivative to preparation of a medicine for treating hyperuricemia or gout, and a pharmaceutical composition for treating hyperuricemia or gout. The structural general formula of the galloyl-glucoside derivative is as shown in the description, wherein R1-R5 are independently selected from H or galloyl. The galloyl-glucoside derivative and the pharmaceutically acceptable salt of the galloyl-glucoside derivative have a remarkable inhibiting effect on xanthine oxidase and can remarkably reduce the uric acid level in blood serum.